| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733610 | Critical Reviews in Oncology/Hematology | 2018 | 27 Pages |
Abstract
Concurrent approaches with temozolomide or bevacizumab do not seem to improve the outcomes of reirradiation and may lead to a higher risk of toxicity but these findings need to be confirmed in prospective series.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Silvia Scoccianti, Giulio Francolini, Giulio Alberto Carta, Daniela Greto, Beatrice Detti, Gabriele Simontacchi, Luca Visani, Muhammed Baki, Linda Poggesi, Pierluigi Bonomo, Monica Mangoni, Isacco Desideri, Stefania Pallotta, Lorenzo Livi,